SCHEMBL844135

SCHEMBL844135

O=C(O)c1cnc2sccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.50
PSMD14 O00487 1/20 0.44
ALDH1A1 P00352 2/20 0.42
GAA P10253 1/20 0.42
P4HA1 P13674 3/20 0.41
P4HTM Q9NXG6 2/20 0.41
SPR P35270 1/20 0.41
MIF P14174 1/20 0.40
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
GABRA4 P48169 1/20 0.39
GABRE P78334 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL455531 0.84 NPC1 (0.40) MGAMPSMD14ALDH1A1GAAHPGD
SCHEMBL4508078 0.84 PSMD14 (0.45) PSMD14KDM4EL3MBTL1NAMPT
Hydrochloric Acid SCHEMBL27679163 0.83 PSMD14 (0.44) PSMD14KDM4EL3MBTL1NAMPT
SCHEMBL1680488 0.80 NPC1 (0.51) PSMD14ALDH1A1HPGDKDM4ENPC1
SCHEMBL27790506 0.80 ADORA2A (0.38) GAAHPGDKDM4ENPC1RAB9A
SCHEMBL3607867 0.77 MAOB (0.50) ALDH1A1GAACYP1A2CYP2C9HPGD
SCHEMBL452095 0.75 MAPT (0.41) CYP1A2HPGDCYP2C19KDM4ERAB9A
SCHEMBL452096 0.75 MAPT (0.41) CYP1A2HPGDCYP2C19KDM4ERAB9A
SCHEMBL21858490 0.75 GABRP (0.44) ALDH1A1GAAP4HTMGABRPGABRD
SCHEMBL19554183 0.74 SERPINE1 (0.52) HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118668266-A Cyanide-free electroless gold plating solution applied to wafer 深圳市溢诚电子科技有限公司 2024-09-20 CN claimed
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 EP disclosed
CN-112566906-B Substituted quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4 多曼治疗学公司 2024-11-12 CN disclosed
CN-118668266-A Cyanide-free electroless gold plating solution applied to wafer 深圳市溢诚电子科技有限公司 2024-09-20 CN disclosed
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-09-19 US disclosed
CN-112204009-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2024-05-07 CN disclosed
EP-3452456-B1 BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2023-07-05 EP disclosed
US-20220106281-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2022-04-07 US disclosed
US-20220089609-A1 SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 DOMAIN THERAPEUTICS (FR) 2022-03-24 US disclosed
EP-3827001-A1 SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 Domain Therapeutics (FR) 2021-06-02 EP disclosed
EP-0757558-A4 SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS ALZA CORP (US) 1999-06-16 EP disclosed
EP-0906115-A1 COMBINED USE OF GnRH AGONIST AND ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 1999-04-07 EP disclosed
EP-0866695-A1 COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS Medinox, Inc. (US) 1998-09-30 EP disclosed
WO-1997040846-A1 COMBINED USE OF GnRH AGONIST AND ANTAGONIST TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-11-06 WO disclosed
CN-1162958-A Thienopyridine or thienopyrimidine derivatives and their use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1997-10-22 CN disclosed
EP-0781774-A2 Prolactin production inhibitory agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-07-02 EP disclosed
WO-1997018805-A1 COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS MEDINOX, INC. (US) 1997-05-29 WO disclosed
EP-0757558-A1 SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS ALZA CORPORATION (US) 1997-02-12 EP disclosed
WO-1995027510-A1 SCREENING METHODS FOR INTEGUMENTAL INFLAMMATION MODULATING AGENTS ALZA CORPORATION (US) 1995-10-19 WO disclosed
CN-1107476-A Heterocyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1995-08-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 MGAM 2521/4885PSMD14 2013/4885ALDH1A1 3433/4885
US-20220106281-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 MGAM 2521/4885PSMD14 2013/4885ALDH1A1 3433/4885
US-20220089609-A1 SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 GRIK4, GRM4, GRIA4 MGAM 4441/4885PSMD14 1450/4885ALDH1A1 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.